Animal Models for Breast Cancer Prevention Research

  • Chunyu Wang
  • Powel H. Brown


Breast cancer is composed of a heterogeneous group of diseases which is characterized by differences in genetic mutations/aberrant oncogene expression, histopathological types, and metastatic potentials. Animal models are valuable tools for defining the molecular pathways in breast carcinogenesis. Various promising chemopreventive agents have been generated to target these pathways, resulting in significant progress in breast cancer prevention research. In this article, we review the animal models of breast cancer, including oncogene (c-Myc, Ras, simian virus 40 (SV40) Tag, erbB2/HER2/neu, Wnt-1, IRS-1 and -2, AIB1/SRC-3, etc.) transgenic mice and tumor suppressor genes (BRCA1, BRCA2, p53, etc.) knockout mice. We discuss the current status of the breast cancer prevention studies, with particular emphasis on chemoprevention using selective estrogen receptor modulators (SERMs), progesterone antagonists, aromatase inhibitors, retinoids/rexinoids, peroxisome proliferator-activated receptor (PPAR) γ ligands, vitamin D receptor ligands, cyclooxygenase-2 (COX-2) inhibitors, tyrosine kinase inhibitors, and anti-erbB2 antibodies. We anticipate that the animal models for breast cancer research provide new tools for understanding the molecular mechanisms of mammary tumorigenesis. By utilizing these animal models more effective chemopreventive drugs and intervention strategies are developed for the prevention of human breast cancer in the future.


Breast Cancer Mammary Tumor Aromatase Inhibitor Mouse Mammary Tumor Virus Breast Cancer Prevention 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abate-Shen C et al (2008) The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges. Cancer Prev Res (Phila) 1(3):161–166Google Scholar
  2. Abbas S, Chang-Claude J, Linseisen J (2009) Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case–control study. Int J Cancer 124(1):250–255PubMedGoogle Scholar
  3. Allred DC et al (1994) The p53 tumor-suppressor gene in human breast cancer. Cancer Treat Res 71:63–77PubMedGoogle Scholar
  4. Andres AC et al (1987) Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice. Proc Natl Acad Sci USA 84(5):1299–1303PubMedGoogle Scholar
  5. Andrulis IL et al (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16(4):1340–1349PubMedGoogle Scholar
  6. Anzano MA et al (1994) Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 54(17):4614–4617PubMedGoogle Scholar
  7. Ariazi EA et al (2006) Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 6(3):181–202PubMedGoogle Scholar
  8. Arun B, Goss P (2004) The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 31(2 Suppl 7):22–29PubMedGoogle Scholar
  9. Avivar A et al (2006) Moderate overexpression of AIB1 triggers pre-neoplastic changes in mammary epithelium. FEBS Lett 580(22):5222–5226PubMedGoogle Scholar
  10. Bakker GH et al (1987) Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treat Rep 71(11):1021–1027PubMedGoogle Scholar
  11. Bakker GH et al (1989) Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. Endocrinology 125(3):1593–1598PubMedGoogle Scholar
  12. Bakker GH et al (1990) Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 37(6):789–794PubMedGoogle Scholar
  13. Baranova A (2008) PPAR ligands as potential modifiers of breast carcinoma outcomes. PPAR Res 2008:230893PubMedGoogle Scholar
  14. Barnes NL et al (2007) Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 96(4):575–582PubMedGoogle Scholar
  15. Basu GD et al (2004) Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2(11):632–642PubMedGoogle Scholar
  16. Baum M et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324):2131–2139PubMedGoogle Scholar
  17. Baum M et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98(9):1802–1810PubMedGoogle Scholar
  18. Benagiano G, Bastianelli C, Farris M (2008a) Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. Expert Opin Pharmacother 9(14):2487–2496PubMedGoogle Scholar
  19. Benagiano G, Bastianelli C, Farris M (2008b) Selective progesterone receptor modulators 2: use in reproductive medicine. Expert Opin Pharmacother 9(14):2473–2485PubMedGoogle Scholar
  20. Benagiano G, Bastianelli C, Farris M (2008c) Selective progesterone receptor modulators 1: use during pregnancy. Expert Opin Pharmacother 9(14):2459–2472PubMedGoogle Scholar
  21. Bennett LM et al (2000) BRCA2-null embryonic survival is prolonged on the BALB/c genetic background. Mol Carcinog 28(3):174–183PubMedGoogle Scholar
  22. Bergman L et al (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356(9233):881–887PubMedGoogle Scholar
  23. Bertone-Johnson ER (2009) Vitamin D and breast cancer. Ann Epidemiol 19(7):462–467PubMedGoogle Scholar
  24. Bertone-Johnson ER et al (2005) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 14(8):1991–1997PubMedGoogle Scholar
  25. Black LJ et al (1994) Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93(1):63–69PubMedGoogle Scholar
  26. Bonneterre J et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18(22):3748–3757PubMedGoogle Scholar
  27. Bortman P et al (2002) Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: a mini review. Braz J Med Biol Res 35(1):1–9PubMedGoogle Scholar
  28. Bosetti C, Gallus S, La Vecchia C (2006) Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17(7):871–888PubMedGoogle Scholar
  29. Bosetti C, Gallus S, La Vecchia C (2009) Aspirin and cancer risk: a summary review to 2007. Recent Results Cancer Res 181:231–251PubMedGoogle Scholar
  30. Bouchard L et al (1989) Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57(6):931–936PubMedGoogle Scholar
  31. Brodie AM et al (1977) The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 100(6):1684–1695PubMedGoogle Scholar
  32. Brown PH, Lippman SM (2000) Chemoprevention of breast cancer. Breast Cancer Res Treat 62(1):1–17PubMedGoogle Scholar
  33. Brown P et al (2007) Prevention of breast cancer using rexinoids: results of a phase II biomarker modulation trial using bexarotene in women at high risk of breast cancer. Breast Cancer Res Treat 106(Suppl):181, #4046Google Scholar
  34. Brown PH et al (2008) Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid. Cancer Prev Res (Phila) 1(3):208–214Google Scholar
  35. Brueggemeier RW, Hackett JC, Diaz-Cruz ES (2005) Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 26(3):331–345PubMedGoogle Scholar
  36. Bui TD et al (1997) A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas. Oncogene 14(10):1249–1253PubMedGoogle Scholar
  37. Campos SM (2004) Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 9(2):126–136PubMedGoogle Scholar
  38. Cauley JA et al (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65(2):125–134PubMedGoogle Scholar
  39. Chambon P (1996) A decade of molecular biology of retinoic acid receptors. FASEB J 10(9):940–954PubMedGoogle Scholar
  40. Chan BT, Lee AV (2008) Insulin receptor substrates (IRSs) and breast tumorigenesis. J Mammary Gland Biol Neoplasia 13(4):415–422PubMedGoogle Scholar
  41. Chappuis PO, Nethercot V, Foulkes WD (2000) Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 18(4):287–295PubMedGoogle Scholar
  42. Chen WS et al (1987) Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature 328(6133):820–823PubMedGoogle Scholar
  43. Chlebowski RT et al (1999) American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 17(6):1939–1955PubMedGoogle Scholar
  44. Chlebowski RT et al (2008) Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 100(22):1581–1591PubMedGoogle Scholar
  45. Chouvet C et al (1986) 1,25-Dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20). J Steroid Biochem 24(1):373–376PubMedGoogle Scholar
  46. Chow LW, Loo WT, Toi M (2005) Current directions for COX-2 inhibition in breast cancer. Biomed Pharmacother 59(Suppl 2):S281–S284PubMedGoogle Scholar
  47. Cocconi G (1994) First generation aromatase inhibitors–aminoglutethimide and testololactone. Breast Cancer Res Treat 30(1):57–80PubMedGoogle Scholar
  48. Colston KW (2008) Vitamin D and breast cancer risk. Best Pract Res Clin Endocrinol Metab 22(4):587–599PubMedGoogle Scholar
  49. Connor F et al (1997) Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet 17(4):423–430PubMedGoogle Scholar
  50. Crowe DL, Chandraratna RA (2004) A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 6(5):R546–R555PubMedGoogle Scholar
  51. Cummings SR et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281(23):2189–2197PubMedGoogle Scholar
  52. Cuzick J (2003) Aromatase inhibitors in prevention – data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163:96–103;discussion 264–266PubMedGoogle Scholar
  53. Cuzick J (2005) Aromatase inhibitors for breast cancer prevention. J Clin Oncol 23(8): 1636–1643PubMedGoogle Scholar
  54. Cuzick J (2008a) Chemoprevention of breast cancer. Breast Cancer 15(1):10–16PubMedGoogle Scholar
  55. Cuzick J (2008b) IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther 8(9):1377–1385PubMedGoogle Scholar
  56. Cuzick J et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360(9336):817–824PubMedGoogle Scholar
  57. Cuzick J et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer–96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99(4):272–282PubMedGoogle Scholar
  58. Cuzick J et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10(5):501–507PubMedGoogle Scholar
  59. Dale TC et al (1996) Compartment switching of WNT-2 expression in human breast tumors. Cancer Res 56(19):4320–4323PubMedGoogle Scholar
  60. D’Ambrosio C et al (1995) Transforming potential of the insulin receptor substrate 1. Cell Growth Differ 6(5):557–562PubMedGoogle Scholar
  61. Dearth RK et al (2006) Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol 26(24):9302–9314PubMedGoogle Scholar
  62. Dearth RK et al (2007) Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 6(6):705–713PubMedGoogle Scholar
  63. Deng CX (2002) Tumor formation in Brca1 conditional mutant mice. Environ Mol Mutagen 39(2–3):171–177PubMedGoogle Scholar
  64. Dillman RO (1999) Perceptions of herceptin: a monoclonal antibody for the treatment of breast cancer. Cancer Biother Radiopharm 14(1):5–10PubMedGoogle Scholar
  65. DiPierri D (1994) RU 486, mifepristone: a review of a controversial drug. Nurse Pract 19(6):59–61PubMedGoogle Scholar
  66. Donehower LA et al (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356(6366):215–221PubMedGoogle Scholar
  67. Du Z, Li Y (2007) RCAS-TVA in the mammary gland: an in vivo oncogene screen and a high fidelity model for breast transformation? Cell Cycle 6(7):823–826PubMedGoogle Scholar
  68. Du Z et al (2006) Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci USA 103(46):17396–17401PubMedGoogle Scholar
  69. Dunn BK, Ryan A (2009) Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators. Ann N Y Acad Sci 1155:141–161PubMedGoogle Scholar
  70. Dunning WF, Curtis MR, Segaloff A (1948) Strain differences in response to diethylstilbestrol and the induction of mammary gland, adrenal and bladder cancer in the rat. J Mich State Med Soc 47(3):305PubMedGoogle Scholar
  71. Dyson N et al (1989) The cellular 107K protein that binds to adenovirus E1A also associates with the large T antigens of SV40 and JC virus. Cell 58(2):249–255PubMedGoogle Scholar
  72. Eccles SA (2001) The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 6(4):393–406PubMedGoogle Scholar
  73. El Etreby MF, Liang Y (1998) Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. Breast Cancer Res Treat 49(2):109–117PubMedGoogle Scholar
  74. Elledge RM, Allred DC (1994) The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 32(1):39–47PubMedGoogle Scholar
  75. Elstner E et al (1998) Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95(15):8806–8811PubMedGoogle Scholar
  76. Esserman LJ et al (1999) Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol Immunother 47(6):337–342PubMedGoogle Scholar
  77. Fabian CJ, Kimler BF (2005) Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol 23(8):1644–1655PubMedGoogle Scholar
  78. Fabian CJ et al (2004) Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res 10(16):5403–5417PubMedGoogle Scholar
  79. Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7(12):937–948PubMedGoogle Scholar
  80. Fereshteh MP et al (2008) The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Res 68(10):3697–3706PubMedGoogle Scholar
  81. Fisher B et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388PubMedGoogle Scholar
  82. Freedman DM et al (2007) Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99(21):1594–1602PubMedGoogle Scholar
  83. Gearing KL et al (1993) Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci USA 90(4):1440–1444PubMedGoogle Scholar
  84. Gennari L (2005) Lasofoxifene (Pfizer). Curr Opin Investig Drugs 6(10):1067–1078PubMedGoogle Scholar
  85. Gibson SL, Ma Z, Shaw LM (2007) Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle 6(6):631–637PubMedGoogle Scholar
  86. Gnanapragasam VJ et al (2001) Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 85(12):1928–1936PubMedGoogle Scholar
  87. Goss PE et al (2007) National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. Clin Breast Cancer 7(11):895–900PubMedGoogle Scholar
  88. Gottardis MM, Jordan VC (1987) Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47(15):4020–4024PubMedGoogle Scholar
  89. Gowen LC et al (1996) Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 12(2):191–194PubMedGoogle Scholar
  90. Graham JD et al (1996) Progesterone receptor A and B protein expression in human breast cancer. J Steroid Biochem Mol Biol 56(1–6 Spec No):93–98PubMedGoogle Scholar
  91. Green JE et al (2000) The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19(8):1020–1027PubMedGoogle Scholar
  92. Grushko TA et al (2004) MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 10(2):499–507PubMedGoogle Scholar
  93. Gulliford T et al (1998) A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 78(1):6–13PubMedGoogle Scholar
  94. Gusterson BA, Williams JC (1981) N-nitrosomethylurea-induced rat mammary tumours as models of human breast cancer. J R Soc Med 74(1):56–59PubMedGoogle Scholar
  95. Guy CT et al (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89(22):10578–10582PubMedGoogle Scholar
  96. Hakem R et al (1996) The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85(7):1009–1023PubMedGoogle Scholar
  97. Hanahan D, Wagner EF, Palmiter RD (2007) The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev 21(18):2258–2270PubMedGoogle Scholar
  98. Harris RE et al (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60(8):2101–2103PubMedGoogle Scholar
  99. Hohenstein P et al (2001) A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage. Oncogene 20(20):2544–2550PubMedGoogle Scholar
  100. Hortobagyi GN (2001) Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 28(6 Suppl 18):43–47PubMedGoogle Scholar
  101. Howe LR (2007) Rexinoids and breast cancer prevention. Clin Cancer Res 13(20):5983–5987PubMedGoogle Scholar
  102. Howe LR, Brown AM (2004) Wnt signaling and breast cancer. Cancer Biol Ther 3(1):36–41PubMedGoogle Scholar
  103. Howe LR et al (2002) Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 62(19):5405–5407PubMedGoogle Scholar
  104. Howe LR et al (2005) HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 65(21):10113–10119PubMedGoogle Scholar
  105. Howell A et al (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62PubMedGoogle Scholar
  106. Huang AL et al (1981) Glucocorticoid regulation of the Ha-MuSV p21 gene conferred by sequences from mouse mammary tumor virus. Cell 27(2 Pt 1):245–255PubMedGoogle Scholar
  107. Huggins C, Grand LC, Brillantes FP (1961) Mammary cancer induced by a single feeding of polymucular hydrocarbons, and its suppression. Nature 189:204–207PubMedGoogle Scholar
  108. Huggins CB, Ueda N, Wiessler M (1981) N-Nitroso-N-methylurea elicits mammary cancer in resistant and sensitive rat strains. Proc Natl Acad Sci USA 78(2):1185–1188PubMedGoogle Scholar
  109. Huguet EL et al (1994) Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res 54(10):2615–2621PubMedGoogle Scholar
  110. Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198(2–3):165–184PubMedGoogle Scholar
  111. Ingraham BA, Bragdon B, Nohe A (2008) Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin 24(1):139–149PubMedGoogle Scholar
  112. Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347(6294):645–650PubMedGoogle Scholar
  113. Issemann I et al (1993) The retinoid X receptor enhances the function of the peroxisome proliferator activated receptor. Biochimie 75(3–4):251–256PubMedGoogle Scholar
  114. Jang TJ et al (2002) Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours. Int J Exp Pathol 83(4):173–182PubMedGoogle Scholar
  115. Janmaat ML, Giaccone G (2003) Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 8(6):576–586PubMedGoogle Scholar
  116. Jemal A et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96PubMedGoogle Scholar
  117. Jerry DJ et al (2000) A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene 19(8):1052–1058PubMedGoogle Scholar
  118. Jonkers J et al (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29(4):418–425PubMedGoogle Scholar
  119. Jordan VC (2007) Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 7(1):46–53PubMedGoogle Scholar
  120. Jordan VC, Allen KE (1980) Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16(2):239–251PubMedGoogle Scholar
  121. Jordan VC, Morrow M (1999) Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20(3):253–278PubMedGoogle Scholar
  122. Jordan VC, Lababidi MK, Langan-Fahey S (1991) Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 83(7):492–496PubMedGoogle Scholar
  123. Kirma N et al (2001) Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice. Cancer Res 61(5):1910–1918PubMedGoogle Scholar
  124. Klijn JG, Setyono-Han B, Foekens JA (2000) Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 65(10–11):825–830PubMedGoogle Scholar
  125. Koeffler HP (2003) Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 9(1):1–9PubMedGoogle Scholar
  126. Kuhn R et al (1995) Inducible gene targeting in mice. Science 269(5229):1427–1429PubMedGoogle Scholar
  127. LaCroix AZ et al (2009) Effects of 5 years of treatment with lasofoxifene on incidence of breast cancer in older women. Cancer Res 69(Suppl 2):11Google Scholar
  128. Lala DS et al (1996) Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 383(6599):450–453PubMedGoogle Scholar
  129. Lange CA (2008) Challenges to defining a role for progesterone in breast cancer. Steroids 73(9–10):914–921PubMedGoogle Scholar
  130. Lanza-Jacoby S et al (2003) The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev 12(12):1486–1491PubMedGoogle Scholar
  131. Lee WH, Boyer TG (2001) BRCA1 and BRCA2 in breast cancer. Lancet 358(Suppl):S5PubMedGoogle Scholar
  132. Lee HJ et al (2008) Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prev Res (Phila) 1(6):476–484Google Scholar
  133. Lehmann JM et al (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270(22):12953–12956PubMedGoogle Scholar
  134. Li Y, Brown PH (2007) Translational approaches for the prevention of estrogen receptor-negative breast cancer. Eur J Cancer Prev 16(3):203–215PubMedGoogle Scholar
  135. Li Y, Brown PH (2009) Prevention of ER-negative breast cancer. Recent Results Cancer Res 181:121–134PubMedGoogle Scholar
  136. Li B et al (1998) A transgenic mouse model for mammary carcinogenesis. Oncogene 16(8):997–1007PubMedGoogle Scholar
  137. Li Y, Hively WP, Varmus HE (2000) Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 19(8):1002–1009PubMedGoogle Scholar
  138. Li SA et al (2002) Prevention of solely estrogen-induced mammary tumors in female aci rats by tamoxifen: evidence for estrogen receptor mediation. J Endocrinol 175(2):297–305PubMedGoogle Scholar
  139. Li Y et al (2007) The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res 13(20):6224–6231PubMedGoogle Scholar
  140. Li Y et al (2008) The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer 98(8):1380–1388PubMedGoogle Scholar
  141. Liang Y et al (2007) Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res 67(20):9929–9936PubMedGoogle Scholar
  142. Liby K et al (2006) The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Cancer Res 12(19): 5902–5909PubMedGoogle Scholar
  143. Liby K et al (2007) A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. Clin Cancer Res 13(20):6237–6243PubMedGoogle Scholar
  144. Liby K et al (2008) Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268. Clin Cancer Res 14(14):4556–4563PubMedGoogle Scholar
  145. Lin SC et al (2004) Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res 64(10):3525–3532PubMedGoogle Scholar
  146. Lippman SM, Lotan R (2000) Advances in the development of retinoids as chemopreventive agents. J Nutr 130(2S Suppl):479S–482SPubMedGoogle Scholar
  147. Lippman ME et al (2006) Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 12(17):5242–5247PubMedGoogle Scholar
  148. List HJ et al (2001) Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat 68(1):21–28PubMedGoogle Scholar
  149. Liu CY et al (1996) Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev 10(14):1835–1843PubMedGoogle Scholar
  150. Liu CH et al (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276(21):18563–18569PubMedGoogle Scholar
  151. Lohrisch C, Piccart M (2001) An overview of HER2. Semin Oncol 28(6 Suppl 18):3–11PubMedGoogle Scholar
  152. Lollini PL et al (2006) Vaccines for tumour prevention. Nat Rev Cancer 6(3):204–216PubMedGoogle Scholar
  153. Lowe LC et al (2005) Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 41(8):1164–1169PubMedGoogle Scholar
  154. Lu S et al (2002) Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer Lett 184(1):7–12PubMedGoogle Scholar
  155. Lu C et al (2003) Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 95(24):1825–1833PubMedGoogle Scholar
  156. Lubet RA et al (1994) Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 15(12):2775–2780PubMedGoogle Scholar
  157. Lubet RA et al (1998) Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis 19(8):1345–1351PubMedGoogle Scholar
  158. Ludwig T et al (1997) Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 11(10):1226–1241PubMedGoogle Scholar
  159. Ludwig T et al (2001) Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev 15(10):1188–1193PubMedGoogle Scholar
  160. Luthra R et al (2003) Use of letrozole as a chemopreventive agent in aromatase overexpressing transgenic mice. J Steroid Biochem Mol Biol 86(3–5):461–467PubMedGoogle Scholar
  161. Macedo LF et al (2008) Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res 68(9):3516–3522PubMedGoogle Scholar
  162. Malaney S, Daly RJ (2001) The ras signaling pathway in mammary tumorigenesis and metastasis. J Mammary Gland Biol Neoplasia 6(1):101–113PubMedGoogle Scholar
  163. Maroulakou IG et al (1994) Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 91(23): 11236–11240PubMedGoogle Scholar
  164. Masamura S et al (1995) Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res Treat 33(1):19–26PubMedGoogle Scholar
  165. Matsumoto H et al (1999) Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice. Oncol Rep 6(2):349–352PubMedGoogle Scholar
  166. Mayr U et al (2008) RCAS-mediated retroviral gene delivery: a versatile tool for the study of gene function in a mouse model of pancreatic cancer. Hum Gene Ther 19(9):896–906PubMedGoogle Scholar
  167. McCormick DL et al (1981) Lifetime dose-response relationships for mammary tumor induction by a single administration of N-methyl-N-nitrosourea. Cancer Res 41(5):1690–1694PubMedGoogle Scholar
  168. McCormick DL et al (1982) Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy. Cancer Res 42(2):508–512PubMedGoogle Scholar
  169. McCullough ML, Bostick RM, Mayo TL (2009) Vitamin d gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 29:111–132PubMedGoogle Scholar
  170. Medina D et al (2002) Environmental carcinogens and p53 tumor-suppressor gene interactions in a transgenic mouse model for mammary carcinogenesis. Environ Mol Mutagen 39(2–3):178–183PubMedGoogle Scholar
  171. Medina D et al (2009) Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. Cancer Prev Res (Phila) 2(2):168–174Google Scholar
  172. Mehta RG et al (1997) Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5. J Natl Cancer Inst 89(3):212–218PubMedGoogle Scholar
  173. Mehta RG et al (2000a) A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 92(5):418–423PubMedGoogle Scholar
  174. Mehta RR et al (2000b) Differentiation of human breast carcinoma cells by a novel vitamin D analog: 1alpha-hydroxyvitamin D5. Int J Oncol 16(1):65–73PubMedGoogle Scholar
  175. Mehta RG et al (2003) Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of Vitamin D. Mutat Res 523–524:253–264PubMedGoogle Scholar
  176. Menard S et al (2004) Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 61(23):2965–2978PubMedGoogle Scholar
  177. Michna H et al (1989a) Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies. Breast Cancer Res Treat 14(3):275–288PubMedGoogle Scholar
  178. Michna H et al (1989b) The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death. J Steroid Biochem 34(1–6):447–453PubMedGoogle Scholar
  179. Mietz JA et al (1992) The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 11(13):5013–5020PubMedGoogle Scholar
  180. Miller VA et al (1996) Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. Clin Cancer Res 2(3):471–475PubMedGoogle Scholar
  181. Moens U et al (1997) Mechanisms of transcriptional regulation of cellular genes by SV40 large T- and small T-antigens. Virus Genes 15(2):135–154PubMedGoogle Scholar
  182. Moulder SL et al (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61(24):8887–8895PubMedGoogle Scholar
  183. Moy B, Goss PE (2006) Lapatinib: current status and future directions in breast cancer. Oncologist 11(10):1047–1057PubMedGoogle Scholar
  184. Muller WJ et al (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54(1):105–115PubMedGoogle Scholar
  185. Nabholtz JM et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18(22):3758–3767PubMedGoogle Scholar
  186. Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4(9):665–676PubMedGoogle Scholar
  187. Nelson MH, Dolder CR (2006) Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40(2):261–269PubMedGoogle Scholar
  188. Nielsen LL et al (1991) Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene. Cancer Res 51(14):3762–3767PubMedGoogle Scholar
  189. Nielsen LL, Gurnani M, Tyler RD (1992) Evaluation of the wap-ras transgenic mouse as a model system for testing anticancer drugs. Cancer Res 52(13):3733–3738PubMedGoogle Scholar
  190. Nielsen LL et al (1995) In wap-ras transgenic mice, tumor phenotype but not cyclophosphamide-sensitivity is affected by genetic background. Anticancer Res 15(2):385–392PubMedGoogle Scholar
  191. Noonberg SB, Benz CC (2000) Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 59(4):753–767PubMedGoogle Scholar
  192. Nusse R, Varmus HE (1982) Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31(1):99–109PubMedGoogle Scholar
  193. Nusse R et al (1984) Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 307(5947):131–136PubMedGoogle Scholar
  194. Olayioye MA et al (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19(13):3159–3167PubMedGoogle Scholar
  195. O’Regan RM et al (2002) Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 94(4):274–283PubMedGoogle Scholar
  196. Palmer CN et al (1994) Interaction of the peroxisome proliferator-activated receptor alpha with the retinoid X receptor alpha unmasks a cryptic peroxisome proliferator response element that overlaps an ARP-1-binding site in the CYP4A6 promoter. J Biol Chem 269(27):18083–18089PubMedGoogle Scholar
  197. Paterson JW (1998) BRCA1: a review of structure and putative functions. Dis Markers 13(4): 261–274PubMedGoogle Scholar
  198. Pegram MD, Konecny G, Slamon DJ (2000) The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 103:57–75PubMedGoogle Scholar
  199. Pelengaris S, Khan M, Evan G (2002) c-MYC: more than just a matter of life and death. Nat Rev Cancer 2(10):764–776PubMedGoogle Scholar
  200. Phillips KA (2000) Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18(21 Suppl):107S–112SPubMedGoogle Scholar
  201. Piccart M et al (2001) The predictive value of HER2 in breast cancer. Oncology 61(Suppl 2):73–82PubMedGoogle Scholar
  202. Poole AJ et al (2006) Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314(5804):1467–1470PubMedGoogle Scholar
  203. Ravdin PM, Chamness GC (1995) The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers–a review. Gene 159(1):19–27PubMedGoogle Scholar
  204. Rendi MH et al (2004) The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. Cancer Res 64(10):3566–3571PubMedGoogle Scholar
  205. Richardson H et al (2007) The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol 14(3):89–96PubMedGoogle Scholar
  206. Ristimaki A et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3):632–635PubMedGoogle Scholar
  207. Rogers AE, Lee SY (1986) Chemically-induced mammary gland tumors in rats: modulation by dietary fat. Prog Clin Biol Res 222:255–282PubMedGoogle Scholar
  208. Rohan TE et al (2009) A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. Breast Cancer Res Treat 116(2):339–350PubMedGoogle Scholar
  209. Rohatgi N, Blau R, Lower EE (2002) Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: a questionnaire study from one physician’s practice. J Womens Health Gend Based Med 11(3):291–301PubMedGoogle Scholar
  210. Rose-Hellekant TA, Sandgren EP (2000) Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice. Oncogene 19(8):1092–1096PubMedGoogle Scholar
  211. Rossouw JE et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333PubMedGoogle Scholar
  212. Rothschild TC et al (1987) Transplacental effects of diethylstilbestrol on mammary development and tumorigenesis in female ACI rats. Cancer Res 47(16):4508–4516PubMedGoogle Scholar
  213. Roy J et al (2003) A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat 81(3):223–229PubMedGoogle Scholar
  214. Ruhlen RL et al (2009) Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model. Breast Cancer Res Treat 117(3):517–524PubMedGoogle Scholar
  215. Rusnak DW et al (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1(2):85–94PubMedGoogle Scholar
  216. Russo J, Russo IH (1996) Experimentally induced mammary tumors in rats. Breast Cancer Res Treat 39(1):7–20PubMedGoogle Scholar
  217. Ryo A et al (2001) Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 3(9):793–801PubMedGoogle Scholar
  218. Salazar LG, Disis ML (2005) Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy. J Clin Oncol 23(30):7397–7398PubMedGoogle Scholar
  219. Sandgren EP et al (1995) Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res 55(17):3915–3927PubMedGoogle Scholar
  220. Santen RJ et al (1999) The potential of aromatase inhibitors in breast cancer prevention. Endocr Relat Cancer 6(2):235–243PubMedGoogle Scholar
  221. Sauer B (1998) Inducible gene targeting in mice using the Cre/lox system. Methods 14(4):381–392PubMedGoogle Scholar
  222. Schneider MR et al (1990) Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J Steroid Biochem Mol Biol 37(6):783–787PubMedGoogle Scholar
  223. Schoenenberger CA et al (1988) Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. EMBO J 7(1):169–175PubMedGoogle Scholar
  224. Serghides L, Kain KC (2005) Peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists have minimal effects on the interaction of endothelial cells with Plasmodium falciparum-infected erythrocytes. Infect Immun 73(2):1209–1213PubMedGoogle Scholar
  225. Sharan SK et al (1997) Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386(6627):804–810PubMedGoogle Scholar
  226. Shellabarger CJ et al (1980) Interaction of dimethylbenzanthracene and diethylstilbestrol on mammary adenocarcinoma formation in female ACI rats. Cancer Res 40(6):1808–1811PubMedGoogle Scholar
  227. Shen Q, Brown PH (2003) Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia 8(1):45–73PubMedGoogle Scholar
  228. Shen Q, Brown PH (2005) Transgenic mouse models for the prevention of breast cancer. Mutat Res 576(1–2):93–110PubMedGoogle Scholar
  229. Shen SX et al (1998) A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 17(24):3115–3124PubMedGoogle Scholar
  230. Shibata MA et al (1996) Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. Cancer Res 56(21):4894–4903PubMedGoogle Scholar
  231. Shin MH et al (2002) Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst 94(17):1301–1311PubMedGoogle Scholar
  232. Shull JD et al (1997) Ovary-intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly develop mammary carcinoma. Carcinogenesis 18(8):1595–1601PubMedGoogle Scholar
  233. Sinn E et al (1987) Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 49(4):465–475PubMedGoogle Scholar
  234. Slamon DJ et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182PubMedGoogle Scholar
  235. Spitz IM (2006) Progesterone receptor antagonists. Curr Opin Investig Drugs 7(10):882–890PubMedGoogle Scholar
  236. Sporn MB (1976) Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36(7 Pt 2):2699–2702PubMedGoogle Scholar
  237. Sporn MB (2004) Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer. Clin Cancer Res 10(16):5313–5315PubMedGoogle Scholar
  238. Sporn MB et al (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35(6):1332–1338PubMedGoogle Scholar
  239. Stewart TA, Pattengale PK, Leder P (1984) Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 38(3):627–637PubMedGoogle Scholar
  240. Strecker TE et al (2009) Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst 101(2):107–113PubMedGoogle Scholar
  241. Suh N et al (1999) A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 59(22):5671–5673PubMedGoogle Scholar
  242. Suh N et al (2001) Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res 61(23):8412–8415PubMedGoogle Scholar
  243. Suh N et al (2002) Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin Cancer Res 8(10):3270–3275PubMedGoogle Scholar
  244. Suzuki A et al (1997) Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 11(10):1242–1252PubMedGoogle Scholar
  245. Tekmal RR et al (1996) Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Res 56(14):3180–3185PubMedGoogle Scholar
  246. Torres-Arzayus MI et al (2004) High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6(3):263–274PubMedGoogle Scholar
  247. Tsukamoto AS et al (1988) Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55(4):619–625PubMedGoogle Scholar
  248. Turashvili G et al (2006) Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 73(5):213–223PubMedGoogle Scholar
  249. Ugolini F et al (2001) WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 20(41):5810–5817PubMedGoogle Scholar
  250. Uray IP, Brown PH (2006) Prevention of breast cancer: current state of the science and future opportunities. Expert Opin Investig Drugs 15(12):1583–1600PubMedGoogle Scholar
  251. Verlinden L et al (2000) Two novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res 60(10):2673–2679PubMedGoogle Scholar
  252. Vogel VG (2009) The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther 9(1):51–60PubMedGoogle Scholar
  253. Vogel VG et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727–2741PubMedGoogle Scholar
  254. Wagner KU et al (1997) Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 25(21):4323–4330PubMedGoogle Scholar
  255. Wakeling AE et al (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62(20):5749–5754PubMedGoogle Scholar
  256. Weaver Z et al (2002) Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 21(33):5097–5107PubMedGoogle Scholar
  257. Welsch CW (1985) Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res 45(8):3415–3443PubMedGoogle Scholar
  258. Welsch CW et al (1981) Effect of an estrogen antagonist (tamoxifen) on the initiation and progression of gamma-irradiation-induced mammary tumors in female Sprague-Dawley rats. Eur J Cancer Clin Oncol 17(12):1255–1258PubMedGoogle Scholar
  259. Welsh J (2007) Vitamin D and prevention of breast cancer. Acta Pharmacol Sin 28(9):1373–1382PubMedGoogle Scholar
  260. Wickerham DL et al (2009) The use of tamoxifen and raloxifene for the prevention of breast cancer. Recent Results Cancer Res 181:113–119PubMedGoogle Scholar
  261. Widschwendter M, Jones PA (2002) DNA methylation and breast carcinogenesis. Oncogene 21(35):5462–5482PubMedGoogle Scholar
  262. William WN Jr et al (2009) Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 8(3):213–225PubMedGoogle Scholar
  263. Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82(2–3):241–250PubMedGoogle Scholar
  264. Wu K et al (2000) 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40T antigen-transgenic mice. Clin Cancer Res 6(9):3696–3704PubMedGoogle Scholar
  265. Wu K et al (2002a) Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 11(5):467–474PubMedGoogle Scholar
  266. Wu K et al (2002b) The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 62(22):6376–6380PubMedGoogle Scholar
  267. Xia W et al (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21(41):6255–6263PubMedGoogle Scholar
  268. Xie SP, Pirianov G, Colston KW (1999) Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. Eur J Cancer 35(12):1717–1723PubMedGoogle Scholar
  269. Xu J, Li Q (2003) Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 17(9):1681–1692PubMedGoogle Scholar
  270. Xu X et al (1999) Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22(1):37–43PubMedGoogle Scholar
  271. Yang LM et al (1999) Role of retinoid receptors in the prevention and treatment of breast cancer. J Mammary Gland Biol Neoplasia 4(4):377–388PubMedGoogle Scholar
  272. Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl 2):1–13PubMedGoogle Scholar
  273. Yin Y et al (2005) Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 65(9):3950–3957PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Clinical Cancer PreventionThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations